|
業務類別
|
Biotechnology |
|
業務概覽
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
| 公司地址
| Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95 |
| 電話號碼
| +353 14378334 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ghres.com |
| 員工數量
| 50 |
| Mr. Aaron Cameron |
Chief Operating Officer |
-- |
27/02/2025 |
| Mr. Magnus Halle |
Managing Director, Ireland |
-- |
27/02/2025 |
| Ms. Julie Ryan, F.C.A. |
Vice President, Finance |
-- |
27/02/2025 |
| Dr. Velichka Valcheva, M.D.,M.Sc. |
Chief Executive Officer |
-- |
27/02/2025 |
|
|
| Dr. Duncan Moore, PhD |
Independent Director |
27/02/2025 |
| Mr. Michael Forer |
Vice Chairman of the Board |
27/02/2025 |
| Mr. Florian Schonharting |
Chairman of the Board |
27/02/2025 |
| Mr. Dermot Hanley |
Independent Director |
27/02/2025 |
|
|
|
|
